Main Uses of Bicalutamide

Bicalutamide is a medication primarily utilized in the management of advanced prostate cancer. It belongs to a class of drugs known as non-steroidal anti-androgens. Its primary function is to block the effects of androgens, such as testosterone, which are hormones that can stimulate the growth of prostate cancer cells.

Treatment of Metastatic Prostate Cancer

In the context of metastatic disease—where the cancer has spread beyond the prostate gland to other parts of the body—bicalutamide is used as part of a combination therapy. It is typically administered alongside a luteinizing hormone-releasing hormone (LHRH) analog. While the LHRH analog works to reduce the total amount of testosterone produced by the body, bicalutamide prevents any remaining testosterone from binding to the receptors on the cancer cells.

Prevention of Tumor Flare

When starting certain hormonal therapies for prostate cancer, there is a risk of a temporary increase in testosterone levels, sometimes referred to as a "tumor flare." This surge can lead to a short-term worsening of symptoms. Bicalutamide is often used during the initial phase of treatment to counteract this effect and stabilize the condition.

Benefits and Goals of Therapy

The integration of bicalutamide into a treatment plan is aimed at achieving several clinical objectives focused on disease control and symptom management.

• Inhibition of Cancer Progression: By blocking the hormonal pathways that prostate cancer cells rely on for growth, the medication helps to slow the progression of the disease.
• Reduction in Tumor Size: Anti-androgen therapy can lead to the shrinkage of the primary tumor and metastatic lesions, which may alleviate pressure on surrounding organs and tissues.
• Symptom Management: For many patients, controlling the growth and spread of the cancer can lead to a reduction in bone pain, urinary difficulties, and other complications associated with advanced prostate cancer.
• Maintenance of Quality of Life: By stabilizing the disease and managing physical symptoms, the therapy aims to help patients maintain their daily activities and overall well-being for a longer period.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adult Males (typically 18 years of age) are the population for whom Bicalutamide is indicated.
Populations for whom use is not recommended	Use in Children and Adolescents (the Pediatric Population) is explicitly not recommended and contraindicated, as safety and efficacy have not been established.
Populations for whom use is contraindicated	Females (all women), Pregnant Women, Breastfeeding Women, and patients with a known hypersensitivity to the drug or any of its components are contraindicated.
Age-related eligibility rules	Adults and Elderly: No routine dosage adjustment is required based solely on age.
Condition-specific eligibility rules	Hepatic Impairment: Use requires caution in patients with moderate to severe hepatic impairment. Renal Impairment: No dosage adjustment is typically necessary.
Pregnancy and lactation eligibility status	Contraindicated in women who are pregnant or may become pregnant, and while breastfeeding.
Eligibility-related restrictions	Patients with rare hereditary problems of galactose intolerance or lactase deficiency should not take this medicine due to the excipient lactose.

---

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is contraindicated in females and the pediatric population.
• Patients must not use Bicalutamide if they have a known hypersensitivity to the active substance or its excipients.
• Use requires caution in patients with moderate to severe liver impairment.

Connection to the overall eligibility profile: The official regulatory profile for Bicalutamide establishes absolute contraindications based on gender, reproductive status, and known allergies, restricting the drug exclusively to adult males. The documents define conditional use parameters, particularly requiring caution for patients with moderate to severe hepatic impairment and excluding groups with specific hereditary intolerances.

Bicalutamide Interactions with other medicines and products

Bicalutamide, primarily metabolized by the cytochrome P450 (CYP) 3A4 enzyme, has the potential to interact with several other medications. These interactions can affect the concentration of either bicalutamide or the interacting drug, potentially altering therapeutic effects or increasing the risk of adverse reactions.

It is crucial to inform your healthcare provider about all medicines you are currently taking, including prescription and non-prescription drugs, herbal supplements, and vitamins.

---

Key Drug Interactions

Type of Interacting Drug	Example Substances	Potential Effect
Anticoagulants	Warfarin, Acenocoumarol	Bicalutamide may enhance the anticoagulant effect, increasing the risk of bleeding. Close monitoring of International Normalized Ratio (INR) is necessary.
CYP3A4 Inhibitors	Ketoconazole, Ritonavir	May increase bicalutamide levels, potentially raising the risk of side effects.
CYP3A4 Inducers	Phenytoin, Rifampicin	May decrease bicalutamide levels, potentially reducing its effectiveness.
Calcium Channel Blockers	Verapamil, Diltiazem	Co-administration may affect the metabolism of either drug.

Bicalutamide's mechanism centers on its role as a Nonsteroidal Antiandrogen (NSAA) that acts through competitive antagonism of the Androgen Receptor (AR), a nuclear receptor found inside target cells. The active component, the (R)-enantiomer, binds directly to the AR's ligand-binding domain, physically blocking the attachment of natural male hormones such as testosterone and dihydrotestosterone (DHT).

The resulting molecular interaction initiates a precise cellular cascade: the drug-bound receptor cannot undergo the necessary conformational change and is prevented from translocating from the cytoplasm into the cell nucleus. This renders the AR complex functionally inactive. Consequently, the receptor cannot bind to Androgen Responsive Elements (AREs) on DNA. This action directly and functionally suppresses the transcription of genes that are dependent on androgen signaling for cell proliferation and survival. This systematic interruption of the molecular growth signal is the core mechanism that produces the systemic antiandrogenic biological effect.

Official Administration Guidelines for Bicalutamide

Bicalutamide is administered exclusively via the oral route as a film-coated tablet, following specific dosing and scheduling rules.

---

Dosage and Frequency

Context of Use	Dosage and Frequency
In combination therapy (with an LHRH analog for metastatic prostate carcinoma)	50 mg once daily
Monotherapy/Adjuvant use (for locally advanced prostate cancer)	150 mg once daily

Both dosage strengths are intended for once daily use, taken at the same time each day, either morning or evening, to maintain consistent drug levels. The tablet may be taken with or without food.

---

Procedural and Course-Duration Principles

For the 50 mg combination regimen, Bicalutamide treatment must be initiated concomitantly (at the same time) as the LHRH analog therapy. For the 150 mg regimen, treatment is generally continuous for a defined course, such as at least two years or until evidence of disease progression.

If a dose is missed, the instruction is to skip the missed dose and take the next dose at the regularly scheduled time; a double dose should not be taken.

No dosage adjustment is necessary for patients with renal impairment, older adults, or those with mild to moderate hepatic impairment, standardizing the use across these patient populations.

Evidence for Advanced and Metastatic Disease

Research exploring Bicalutamide's application in advanced or metastatic prostate cancer has involved large-scale Phase 3 Randomized Controlled Trials (RCTs). These studies involved comparisons of the drug in a combination regimen with an LHRH analog against the LHRH analog used as a single agent. Researchers focused on monitoring key measurements, such as Overall Survival (OS) measurements of the study participants and the time until signs of disease progression were observed. Research also examined changes in the biomarker Prostate-Specific Antigen (PSA), reporting the rate of response and the lowest level achieved (nadir).

Evidence for Locally Advanced Disease and Recurrence

Bicalutamide was also evaluated in large, multi-year trials for men with localized or locally advanced prostate cancer, studied as a single agent or as an adjunct to local treatments like radiation or surgery. These trials monitored Progression-Free Survival (PFS) measurements. Separately, Phase 3 RCTs explored its application in men experiencing a rising PSA level (biochemical recurrence) after initial therapy. These studies monitored outcomes such as the time until the PSA level progressed (failed) and the rate of progression to distant metastasis observed in the study populations.

Study Durability and Research Gaps

The overall evidence includes extended follow-up durations in several major trial programs, tracking cohorts for over a decade. These long-term studies provide context regarding the durability of measured outcomes over many years. However, research highlights key limitations. Findings regarding Overall Survival were mixed when evaluated across specific subgroups, meaning certainty is reduced for certain patient groups. Furthermore, Bicalutamide primarily serves as a baseline comparator in more recent trials, and the evidence for its use in certain advanced settings is largely based on older studies.

Key Studies & References

1. Overall survival with bicalutamide in patients with locally advanced prostate cancer: a randomised, double-blind, placebo-controlled multicentre trial
2. Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy (RTOG 9601)

Common questions about Bicalutamide (FAQ)

---

Q: What kind of medication is Bicalutamide?

Bicalutamide belongs to a class of medicines called non-steroidal antiandrogens. According to regulatory documents, this medicine works by blocking the effects of androgens, which are male sex hormones that can stimulate the growth of prostate cancer cells. By interfering with these actions, Bicalutamide is intended to slow the progression of the tumor.

Q: Does Bicalutamide affect fertility in men?

Official information indicates that Bicalutamide may have an effect on male fertility. However, this effect is often noted as potentially reversible after treatment is stopped. Men who are considering having children should discuss fertility options with a healthcare professional.

Q: What are Bicalutamide's approved medical uses?

Regulatory documents state that Bicalutamide is indicated for the treatment of advanced prostate cancer. It is typically used in combination with another type of hormonal therapy, specifically an LHRH (luteinizing hormone-releasing hormone) analogue, or alongside surgical removal of the testicles.

Q: How long does Bicalutamide stay in the body after stopping treatment?

Studies on Bicalutamide show that the active part of the drug has a long half-life, meaning it takes a significant amount of time to be fully eliminated from the body. The main active component (R-enantiomer) accumulates in the body with daily administration and has an elimination half-life of about one week.

Q: Can Bicalutamide affect my blood tests or medical procedures?

Official information indicates that Bicalutamide may affect the results of certain medical tests, such as the Prostate Specific Antigen (PSA) test used to monitor prostate cancer. Patients are generally advised to inform all treating healthcare providers that they are taking this medicine, especially before any procedures or tests.

Q: Are there any precautions regarding sunlight while taking Bicalutamide?

Regulatory sources advise patients to avoid direct exposure to excessive sunlight or UV-light while taking Bicalutamide. This is a precaution related to a reported, though rare, risk of photosensitivity reactions.

Q: Can Bicalutamide be used for localized or early-stage prostate cancer?

According to the official product information, Bicalutamide is not indicated for early phase (localized) prostate cancer that is being managed by 'watchful waiting' (monitoring without active treatment). Its approved use is for advanced prostate cancer.

Q: Does Bicalutamide contain lactose?

Regulatory documents indicate that Bicalutamide tablets contain lactose. This information is important for patients who have conditions such as hereditary galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption.

Storage and Disposal Requirements for Bicalutamide Tablets

Bicalutamide tablets must be stored at controlled room temperature, maintaining a specific range of 68 F to 77 F (20 C to 25 C), as defined in official regulatory documents. The medication must be preserved in a tightly closed container to protect its integrity.

Storage Classification	Requirement
Temperature	Controlled Room Temperature (20 C to 25 C)
Container	Kept Tightly Closed
Child Safety	Out of the sight and reach of children

All medications, including Bicalutamide, must be kept out of the sight and reach of children for safety. The official disposal instruction is to discard any unused product or waste material in accordance with local requirements for pharmaceutical waste.